SEC Form 4 · accession 0000921895-17-000105
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Alan Rosenberg
Director
Period of report
Jan 24, 2017
Accepted (ET)
Jan 26, 2017 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 24, 2017 | M | 14,245 | — | A | 69,370 | D | |
| Common Stock | holding | — | — | — | 55,125 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Jan 24, 2017 | M | 14,245 | A | — | — | Common Stock | 14,245 | 0 | D |
Explanation of responses
- F1As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person.
- F2On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above.